Appendix of investigators on p. 787.
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis†
Article first published online: 21 APR 2006
Copyright © 2006 American Neurological Association
Annals of Neurology
Volume 59, Issue 5, pages 780–787, May 2006
How to Cite
Panitch, H. S., Thisted, R. A., Smith, R. A., Wynn, D. R., Wymer, J. P., Achiron, A., Vollmer, T. L., Mandler, R. N., Dietrich, D. W., Fletcher, M., Pope, L. E., Berg, J. E. and Miller, A. (2006), Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol., 59: 780–787. doi: 10.1002/ana.20828
- Issue published online: 21 APR 2006
- Article first published online: 21 APR 2006
- Manuscript Accepted: 6 FEB 2006
- Manuscript Revised: 3 JAN 2006
- Manuscript Received: 25 MAY 2005
- Avanir Pharmaceuticals. Grant Number: 02-AVR-106
To evaluate the efficacy and safety of DM/Q (capsules containing dextromethorphan [DM] and quinidine [Q]) compared with placebo, taken twice daily, for the treatment of pseudobulbar affect over a 12-week period in multiple sclerosis patients.
A total of 150 patients were randomized in a double-blind, placebo-controlled study to assess pseudobulbar affect with the validated Center for Neurologic Study-Lability Scale. Each patient also recorded the number of episodes experienced between visits, estimated quality of life and quality of relationships on visual analog scales, and completed a pain rating scale.
Patients receiving DM/Q had greater reductions in Center for Neurologic Study-Lability Scale scores than those receiving placebo (p < 0.0001) at all clinic visits (days 15, 29, 57, and 85). All secondary end points also favored DM/Q, including the number of crying or laughing episodes (p ≤ 0.0077), quality of life (p < 0.0001), quality of relationships (p = 0.0001), and pain intensity score (p = 0.0271). DM/Q was well tolerated; only dizziness occurred with greater frequency than with placebo.
Results in multiple sclerosis patients were similar to those of a previous study in amyotrophic lateral sclerosis, demonstrating that DM/Q may be beneficial in treating potentially disabling pseudobulbar affect in a variety of neurological disorders. Ann Neurol 2006;59:780–787